- Home
- THAR
THAR
Tharimmune Inc.
as 12-18-2024 10:43am EST
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | BRIDGEWATER |
| Market Cap: | 2.8M | IPO Year: | 2022 |
| Target Price: | N/A | AVG Volume (30 days): | 232.7K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -11.95 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.83 - $8.55 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Tharimmune Inc. (THAR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Appajosyula Sireesh | THAR | Chief Operating Officer | Nov 13 '24 | Buy | $2.02 | 5,000 | $10,096.00 | 10,758 | |
| MILBY RANDY | THAR | CEO | Oct 8 '24 | Buy | $2.09 | 2,500 | $5,221.04 | 11,934 | |
| Appajosyula Sireesh | THAR | Chief Operating Officer | Oct 8 '24 | Buy | $1.93 | 5,000 | $9,650.00 | 10,758 |
Latest Tharimmune Inc. News
THAR Breaking Stock News: Dive into THAR Ticker-Specific Updates for Smart Investing
ACCESSWIRE
2 days ago
Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update
ACCESSWIRE
12 days ago
Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs
ACCESSWIRE
21 days ago
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025
ACCESSWIRE
a month ago
Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease
ACCESSWIRE
a month ago
Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics
ACCESSWIRE
a month ago
Tharimmune Announces Upcoming Conference Presentations
ACCESSWIRE
2 months ago
Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis
ACCESSWIRE
2 months ago
Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting
Compare THAR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "THAR Tharimmune Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.